HomepageCGEN • NASDAQ
add
Compugen Ltd
Vorige slotkoers
$Â 1,41
Dag-range
$Â 1,37 - $Â 1,54
Jaar-range
$Â 0,62 - $Â 3,03
Beurswaarde
136,10Â mln. USD
Gem. volume
262,37K
Koers/winst
79,29
Dividendrendement
-
Primaire beurs
NASDAQ
In het nieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
(USD) | sep 2024info | Wijziging j-o-j |
---|---|---|
Opbrengst | 17,13 mln. | — |
Bedrijfskosten | 9,04Â mln. | -14,99% |
Netto inkomsten | 1,28Â mln. | 112,95% |
Netto winstmarge | 7,45 | — |
Winst per aandeel | 0,01 | 109,09% |
EBITDA | 4,62Â mln. | 143,92% |
Effectief belastingtarief | 77,92% | — |
Balans
Totale activa
Totale passiva
(USD) | sep 2024info | Wijziging j-o-j |
---|---|---|
Contanten en kortetermijnbeleggingen | 112,71Â mln. | 95,99% |
Totale activa | 123,52Â mln. | 82,69% |
Totale passiva | 63,03Â mln. | 338,18% |
Totaal aandelenvermogen | 60,49 mln. | — |
Uitstaande aandelen | 89,54 mln. | — |
Koers-boekwaardeverhouding | 2,07 | — |
Rendement op activa | 9,62% | — |
Rendement op kapitaal | 18,01% | — |
Kasstroom
Nettomutatie in liquide middelen
(USD) | sep 2024info | Wijziging j-o-j |
---|---|---|
Netto inkomsten | 1,28Â mln. | 112,95% |
Operationele kasstroom | — | — |
Kasstroom uit beleggingen | — | — |
Kasstroom uit financiering | — | — |
Nettomutatie in liquide middelen | — | — |
Vrije kasstroom | — | — |
Over
Compugen Ltd. is a clinical-stage publicly traded predictive drug discovery and development company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Compugen was established as computational drug discovery service provider in 1993. Compugen originally acted as service provider for pharma companies, supplying its software and computational services to predict different types of biological phenomena. It had arrangements with big companies such as Novartis AG, Abbot Laboratories and Pfizer Inc. Subsequently, Compugen made a decision to become a drug development company with its own internal pipeline, and in 2010, decided to a focus on oncology and immunology. OncoMed Pharmaceuticals and Five Prime Therapeutics are among Compugen's competitors. Wikipedia
Opgericht
10 feb 1993
Website
Werknemers
68